Clinical trials: Lassa Fever
Healthy
Multiple Ascending Oral Dose 14-Day Trial of LHF-535 in Healthy Participants
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of a daily oral dose of LHF-535 administered for 14 days to healthy participants.
- Trial name
- NCT03993704
- Testing
- LHF-535
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Kineta Inc.
Ebola Hemorrhagic Fever, Lassa Hemorrhagic Fever
Clinical Validation of Isothermal Nucleic Acid Amplification Bioassays Modules - GUINEA
This study aim to validate the clinical performances of two newly developed isothermal nucleic acid amplification bioassays modules for EBOV and LASV.
- Trial name
- NCT07681752
- Testing
- FORTIFIEDx and DECIPHER bioassays
- Volunteers
- 150 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Lassa Fever
ISTH/ANRS 0409s INTEGRATE Lassa Fever Study
Lassa fever (LF) is a viral haemorrhagic fever responsible of 5000 deaths per year in West Africa, with in-hospital mortality at 12%.
- Trial name
- NCT06212336
- Testing
- Favipiravir, Ribavirin, Dexamethasone
- Where
- 4 sites in Liberia, Nigeria
- Volunteers
- 1,755 people
- Sponsor
- Irrua Specialist Teaching Hospital
Lassa Virus Infection
Seroprevalence and Incidence of Lassa Fever in the Rural Commune of Sibirila, District of Bougouni, Mali
Background: Lassa fever is very similar to other diseases that cause fever, such as malaria and yellow fever. People get Lassa fever from mice. A person can get Lassa fever from mice urine and droppings.
- Trial name
- NCT02311387
- Where
- Mali
- Volunteers
- 601 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lassa Fever
DMID 23-0015; Lassa Fever CVD 1000
This study proposes the evaluation of a novel, first-in-human Lassa fever vaccine based on the complete Lassa glycoprotein complex (GPC) antigen.
- Trial name
- NCT06546709
- Testing
- LASSARAB+ aPHAD-SEat 700rU, HDCV Comparator, LASSARAB+ aPHAD-SEat 1400rU
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wilbur Chen, MD, MS
Lassa Fever
Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana
This is a randomized, blinded, placebo-controlled trial to evaluate the safety, tolerability and immunological profile of INO-4500 administered by intradermal (ID) injection followed by electroporation (EP) using CELLECTRA™ 2000…
- Trial name
- NCT04093076
- Testing
- INO-4500, CELLECTRA™ 2000
- Where
- Ghana
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Inovio Pharmaceuticals
Lassa Fever
A Trial to Evaluate the Safety, Immunogenicity and the Optimal Dose of MOPEVAC-Las Vaccine Candidate Against Lassa Fever
Lassa fever is an acute viral disease belonging to the category of viral hemorrhagic fevers. It is endemic in West Africa. Outbreaks occur every year, and it is estimated that between 100 000 and 300 000 individuals are infected…
- Trial name
- FIRST-IN-MOP (NCT07833436)
- Testing
- Low dose MOPEVAC-Las vaccine, Intermediate dose MOPEVAC-Las vaccine, High dose MOPEVAC-Las vaccine
- Where
- France
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Lassa Fever
Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers
This is a randomized and double-blinded within study group, placebo-controlled trial to evaluate the safety, tolerability and immunological profile of INO-4500 administered by intradermal (ID) injection followed by…
- Trial name
- NCT03805984
- Testing
- INO-4500, CELLECTRA® 2000
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Inovio Pharmaceuticals
Lassa Fever
LAssa Fever Adjunct Treatment With DEXamethasone
Dexamethasone is a corticosteroid which can modulate inflammatory-mediated tissue damage associated with a wide range of infectious diseases.
- Trial name
- LADEX (NCT06222723)
- Testing
- Dexamethasone, Ribavirin
- Where
- Nigeria
- Volunteers
- 42 people
- Sponsor
- Bernhard Nocht Institute for Tropical Medicine
Crimean-Congo Hemorrhagic Fever, Lassa Fever
Treatment of Viral Hemorrhagic Fevers With Intravenous Ribavirin in Military Treatment Facilities
This is a Phase 2 study of the safety and efficacy of Intravenous (IV) Ribavirin in treating patients presenting with a probable or suspected case of viral hemorrhagic fever (either Crimean Congo or Lassa Fever) at a military…
- Trial name
- NCT00992693
- Testing
- Ribavirin (Virazole) Injection
- Where
- Germany
- Sponsor
- U.S. Army Medical Research and Development Command
Lassa Virus Infection
A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001)
This is a randomized, placebo-controlled, single-center, dose finding phase I trial in healthy adult volunteer participants consisting of two phases, an unblinded dose escalation and an observer-blinded treatment phase.
- Trial name
- NCT04055454
- Testing
- MV-LASV
- Where
- Belgium
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Themis Bioscience GmbH
Viral Hemorrhagic Fever
Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever
Is ribavirin a therapeutic option for patients with a probable or suspected case of viral hemorrhagic fever?
- Trial name
- NCT02483260
- Testing
- Ribavirin
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- U.S. Army Medical Research and Development Command
Lassa Fever
Cardiovascular Function and Ribavirin PK/PD in Lassa Fever in Lassa Fever
Arenaviruses are included in the World Health Organisation R\&D Blueprint list of high priority pathogens, since this virus group includes several epidemic-prone highly pathogenic viruses for which there are inadequate…
- Trial name
- NCT04285034
- Where
- Nigeria
- Volunteers
- 158 people
- Sponsor
- University of Oxford
Lassa Fever, Lassa Virus Infection
A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Heath
A Phase 1 Randomized, Double-blinded, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Health
- Trial name
- NCT04794218
- Testing
- rVSV∆G-LASV-GPC
- Where
- 4 sites in United States, Liberia
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
Lassa Fever, Lassa Virus Infection
Lassa Fever Clinical Course and Prognostic Factors in Nigeria
The investigators propose to conduct a nationwide (Nigeria), prospective, non-interventional cohort study describing the clinical course, biological characteristics, case management and outcomes in patients hospitalized for a…
- Conditions
- Lassa Fever, Lassa Virus Infection, Pregnancy Complications, Acute Kidney Injury
- Trial name
- LASCOPE (NCT03655561)
- Testing
- Non interventional research
- Where
- 2 sites in Nigeria
- Volunteers
- 1,200 people
- Sponsor
- Alliance for International Medical Action
Lassa Fever
Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever
This exploratory, prospective, controlled, multisite, open label, randomized clinical trial with two treatment arms aims to compare favipiravir, a new treatment candidate for Lassa fever (LF), with the current standard of care…
- Trial name
- SAFARI (NCT04907682)
- Testing
- Ribavirin iv, Favipiravir
- Where
- 2 sites in Nigeria
- Volunteers
- 40 people
- Sponsor
- Bernhard Nocht Institute for Tropical Medicine
Lassa Fever
Cardiovascular Function and Ribavirin Pharmacokinetics and Pharmacodynamics in Patients With Lassa Fever
Lassa fever carries a treated mortality in hospitalized patients of up to 50%. Lassa fever is often described as being characterized by vascular leak and shock in the terminal phase, but, whilst animal data supports this, there…
- Trial name
- NCT03889106
- Testing
- Ribavirin
- Where
- Sierra Leone
- Volunteers
- 2 people
- Sponsor
- University of Oxford
Lassa Fever
A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults and Children Residing in West Africa
- Trial name
- NCT05868733
- Testing
- Day 1 Dose (2×106 pfu), Day 1 Dose (1×107 pfu), Day 1 Dose (2×10^5 pfu)
- Where
- 3 sites in Ghana, Liberia and 1 more
- Volunteers
- 530 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
Lassa Virus Infection
Prevalence and Incidence of Lassa Virus Infection in Southern Mali
Background: The disease Lassa fever mostly affects people in Western Africa. It is very similar to other diseases that cause fever, like malaria and yellow fever. People get Lassa fever from mice infected with Lassa virus.
- Trial name
- NCT03783143
- Where
- Mali
- Volunteers
- 8,524 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lassa Fever
ARN-75039 Lassa Fever Treatment in West Africa
This multicenter, randomized, open-label Phase 2 clinical trial evaluates the safety, tolerability, and virologic efficacy of ARN-75039, a novel oral antiviral, for treating Lassa fever in hospitalized adults in West Africa.
- Trial name
- NCT07419373
- Testing
- ARN-75039 high, Intravenous ribavirin, ARN-75039 low
- Where
- 4 sites in United States, Nigeria
- Volunteers
- 135 people
- Sponsor
- Arisan Therapeutics, Inc.